Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.
• \* Willingness to provide written informed consent before any study-specific procedures or activities are performed
‣ Age ≥ 18 years of age, at the time of consent
⁃ Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed
⁃ History of prior vaccination against common VPD
⁃ Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days
⁃ Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus